Mantle Cell Lymphoma

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Andre Goy, MD, MS, compares the toxicity profiles of available BTK inhibitors in mantle cell lymphoma.

Michael Wang, MD, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

David Miklos, MD, discusses alternative options to the investigational CAR T-cell therapy KTE-X19 for patients with relapsed/refractory mantle cell lymphoma, while awaiting a regulatory decision from the FDA.

Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.

David Miklos, MD, discusses anticipated sequencing challenges with the investigational CAR T-cell therapy KTE-X19 in mantle cell lymphoma.

During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts discussed several novel treatments that are changing the relapsed/refractory mantle cell lymphoma treatment landscape, including Bruton tyrosine kinase (BTK) inhibitors, BTK combinations, and chimeric antigen receptor T-cell therapy.

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the use of bendamustine and rituximab (Rituxan) as induction therapy in mantle cell lymphoma (MCL).

Michael Wang, MD, discusses the implications of the ZUMA-2 trial for patients with relapsed/refractory mantle cell lymphoma and other targeted therapies on the horizon.

Andre Goy, MD, MS, discusses the paradigm shift in the treatment of patients with mantle cell lymphoma that has occurred over the past decade.

Andre Goy, MD, MS, discusses the utility of BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses ongoing research in mantle cell lymphoma (MCL).

Findings from the pivotal phase II ZUMA-2 trial of KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma were published in the New England Journal of Medicine, as the FDA considers a biologics license application for the CAR T-cell therapy for an approval in this setting.

David Miklos, MD, discusses the safety profile of KTE-X19 in mantle cell lymphoma.

Hun Ju Lee, MD, discusses the implications of phase I results regarding the combination of carfilzomib and ibrutinib in relapsed/refractory mantle cell lymphoma.

Reid W. Merryman, MD, discusses the impact of adding high-dose cytarabine to bendamustine and rituximab as an induction regimen for patients with mantle cell lymphoma.

Combination therapy with cirmtuzumab and ibrutinib induced a 50% complete response rate in the phase I/II CIRLL study.

Diego Villa, MD, MPH, discusses the findings of a retrospective analysis looking at bendamustine plus rituximab in mantle cell lymphoma.

David Ritchie, MD, PhD, discusses immunological recovery with venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma.

Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, according to results from the phase II ZUMA-2 trial.

David Miklos, MD, discusses the results from the ZUMA-2 trial evaluating KTE-X19 in patients with relapsed/refractory mantle cell lymphoma.

Diego Villa, MD, MPH, discusses the benefit of bendamustine and rituximab versus R-CHOP in transplant-eligible and -ineligible patients with mantle cell lymphoma.

David Ritchie, MD, PhD, discusses the rationale of the AIM trial in relapsed/refractory mantle cell lymphoma (MCL).

Andre Goy, MD, MS, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma.